Tiziana Life Sciences Granted FDA Fast Track Designation
24 juil. 2024 07h00 HE
|
Tiziana Life Sciences Ltd.
NEW YORK, July 24, 2024 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with...
Kane Biotech Receives FDA Approval to Increase Dosage Allowance of its revyve™ Antimicrobial Wound Gel
23 juil. 2024 08h30 HE
|
Kane Biotech Inc.
WINNIPEG, Manitoba, July 23, 2024 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX- V:KNE; OTCQB:KNBIF) (“Kane Biotech”, “Kane” or the “Company”) announces that the US Food and Drug Administration (FDA)...
Radical™ Catheter Technologies Presents Analysis of Disruptive, Recently FDA-Cleared Endovascular Technology at the Society of NeuroInterventional Surgery (SNIS) 21st Annual Meeting
22 juil. 2024 17h00 HE
|
Radical Catheter Technologies
CAMPBELL, Calif., July 22, 2024 (GLOBE NEWSWIRE) -- Radical™ Catheter Technologies, a medical device company pioneering the next generation of endovascular access and delivery products, today...
Takeda’s Eohilia Sees Strong Early Adoption and Growth Potential in Eosinophilic Esophagitis, According to Spherix Global Insights
18 juil. 2024 10h05 HE
|
Spherix Global Insights
EXTON, PA, July 18, 2024 (GLOBE NEWSWIRE) -- In February of this year, Takeda’s Eohilia (budesonide oral suspension) received FDA approval as the first and only oral therapy for eosinophilic...
Longeveron® Announces U.S. FDA Grants Fast Track Designation for Lomecel-B™ for the Treatment of Mild Alzheimer’s Disease
17 juil. 2024 08h00 HE
|
Longeveron
Longeveron announces FDA has granted Fast Track designation to cellular therapy Lomecel-B(TM) for the treatment of mild Alzheimer’s Disease.
Clearmind Medicine Obtains IND Approval from the FDA to Start the Phase I/IIa Clinical Trial with its Innovative Treatment for Alcoholism
16 juil. 2024 09h02 HE
|
Clearmind Medicine Inc.
Vancouver, Canada, July 16, 2024 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or the "Company"), a clinical-stage biotech company focused on discovery and...
Kronos Advanced Technologies Inc. Warns Consumers to Use Only FDA-Cleared Air Purifiers at Home and Office
16 juil. 2024 06h18 HE
|
Kronos Advanced Technologies Inc.
Los Angeles, CA , July 16, 2024 (GLOBE NEWSWIRE) -- Los Angeles, CA July 16, 2024 (GLOBE NEWSWIRE) -- KRONOS ADVANCED TECHNOLOGIES, INC. (OTC MARKETS: KNOS) ("KNOS" or the "Company"), an...
60 Degrees Pharma Announces IRB Approval of Clinical Study of Tafenoquine for Treatment of Babesiosis in Immunocompromised Patients with Persistent Babesia microti Despite Prior Treatment
09 juil. 2024 06h31 HE
|
Sixty Degrees Pharmaceuticals
60 Degrees Pharma wins IRB approval for tafenoquine study for treating persistent babesiosis in immunocompromised patients despite prior treatment.
SeaStar Medical Finalizes FDA Labeling Requirement for QUELIMMUNE, Paving the Way for First Commercial Sales as Humanitarian Use Device
03 juil. 2024 08h30 HE
|
SeaStar Medical Holding Corporation
DENVER, July 03, 2024 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU), a commercial-stage medical device company developing proprietary solutions to reduce the consequences of...
On Path to First-in-Human Study, NurExone Engages Prominent Expert in Biological Drug Development
21 juin 2024 16h04 HE
|
NurExone Biologic Inc
TORONTO and HAIFA, Israel, June 21, 2024 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX), (OTCQB: NRXBF), (Germany: J90) (the “Company” or “NurExone”), a pioneering biopharmaceutical company,...